ClinicalTrials.gov
public full text
Public Domain
Azacytidine and Valproic Acid in Patients With Advanced Cancers
Primary Objective: 1\. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in patients with advanced cancer. Secondary Objectives: 1. To perform a preliminary assessment of the histone acetylation and DNA methylation effects of this combination on peripheral blood mononuclear cells (PBMC). 2. To assess the clinical anti-tumor activity (objective response including complete and partial responses) of this combination in patients with advanced cancer, in a descriptive fashion.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)#838647
- Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer#1009115
- Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma#1171712
- Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer#1153131
- Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer#1363545
Record · ID 1309382
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive